Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Magnesium sulfate + sodium bicarbonate is an investigational combination therapy developed by researchers at West China Hospital, Sichuan University, for the treatment of knee osteoarthritis. Administered via intra-articular injection, the formulation utilizes a dual mechanism to address joint pain and cartilage degradation. Magnesium sulfate acts as a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist and a calcium channel blocker, providing analgesic and anti-inflammatory effects by inhibiting pain signaling pathways. Sodium bicarbonate serves as an alkalizing agent that neutralizes the acidic microenvironment (acidosis) typically found in osteoarthritic joints, which is associated with increased pain sensitization and accelerated cartilage breakdown. By combining these agents, the therapy aims to improve joint function and provide symptomatic relief by modifying the biochemical and physical environment of the synovial space.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium sulfate + sodium bicarbonate.